Greater Bay Airlines on Tuesday announced the cancellation of flights, which could disrupt the plans of some Lunar New Year travellers. The airline did not specify the number of flights affected ...

Since the beginning of all things. The Emperor of Mankind has stood as the light in the darkness. We sisters, ordained and consecrated in battle, defend that beacon against all who come against it – ...

PARMA, Ohio — Greater Cleveland’s shoppers will finally get another option for groceries, now that another national chain is officially entering the market. Grocery Outlet Bargain Markets will ...

Ah, the scorpion lollipop, a symbol of the Sonoran Desert. I like them, if only for the campiness of the dark, goth-looking scorpion encased unhappily in a gentle green, pink or blue. That said, ...

Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics ...

We look forward to leveraging the great work of the Scorpion team to date, along with Lilly's deep expertise in breast cancer, to further advance STX-478 with speed and focus." Under the terms of ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of ...

SAN FRANCISCO — Eli Lilly said Monday it would acquire a cancer program from startup Scorpion Therapeutics in a deal worth up to $2.5 billion, as the Indianapolis company broadens its pipeline.

Eli Lilly has turned to a biotechnology startup for help building its pipeline of cancer drugs, agreeing on Monday to purchase an experimental cancer drug from privately held Scorpion Therapeutics for ...

Investing.com -- Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant tech. company of fraudulent practices, including ...